Trials / Withdrawn
WithdrawnNCT01244009
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
A Phase II Efficacy Study of MK-4827 in Patients With Mantle Cell Lymphoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Tesaro, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the efficacy and safety of MK-4827 in participants with relapsed mantle cell lymphoma (MCL) and in a subset of participants with inactivation of the Ataxia-Telangiectasia Mutated (ATM) gene.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-4827 | MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2010-11-19
- Last updated
- 2016-11-07
Source: ClinicalTrials.gov record NCT01244009. Inclusion in this directory is not an endorsement.